Journal of Interventional Cardiac Electrophysiology· 2026Q2
Vascular closure with a suture retention device versus suture-mediated closure system after large bore venous access for electrophysiologic procedures
- 0citations
- Q2SCImago
- 2026year
Short summary
The LockeT suture retention device resulted in fewer access-site complications (1.2% vs. 9.3%) and device failures (0.0% vs. 4.7%) compared to the Perclose ProGlide suture-mediated system after large bore venous access for electrophysiologic procedures, despite similar time to hemostasis.
AI-generated from the title and abstract; the full text is not read.
Key points
- LockeT device use was associated with fewer cumulative access-site complications (1.2% vs. 9.3%, p=0.017) and device failures (0.0% vs. 4.7%, p=0.023) compared to Perclose ProGlide.
- Time to hemostasis was similar between LockeT (20 IQR 7-103 min) and Perclose (18 IQR 8-66 min).
- Time to ambulation was significantly longer with LockeT (4.3 IQR 3.7-5.1 hours) versus Perclose (2.9 IQR 2.5-4.1 hours, p<0.001).
- Same-day discharge rates were similar for both devices (84.9% vs. 87.2%).
AI-generated from the title and abstract; the full text is not read.
Abstract
BACKGROUND: The LockeT is a suture retention device that may be a postoperative closure option for electrophysiologic procedures requiring large-bore vascular access (LBVA) but warrants further evaluation. OBJECTIVES: We compare the use of LockeT to a suture-mediated vascular closure device for LBVA after left atrial appendage occlusion (LAAO). METHODS: We performed a retrospective study of LBVA after LAAO from March 2023 to August 2024 using LockeT or Perclose ProGlide. Endpoints included access-site-related complications, time to hemostasis (TTH), time to ambulation (TTA), and same-day discharge (SDD). RESULTS: We identified 208 patients (n) who underwent either LockeT (n = 86; N = 172) or Perclose (n = 122; N = 362) devices. Even after propensity score matching (LockeT: n = 86; and Perclose: n = 86), those undergoing LockeT had few differences in baseline characteristics and were associated with more frequent Amulet (62.8% vs. 16.3%) than Watchman (37.2% vs. 68.6%) LAAO implantation. The LockeT was associated with no difference in TTH (20 [interquartile range (IQR) 7.0-103.0] vs. 18.0 [IQR 8.0-66.0] min, p = 0.833) and higher TTA (4.3 [IQR 3.7-5.1] vs. 2.9 [2.5-4.1] hours, p < 0.001). There were fewer cumulative access-site complications (1.2% vs. 9.3%, p = 0.017) and device failures (0.0% vs. 4.7%, p = 0.023), and similar same-day discharges (84.9% vs. 87.2%, p = 0.66). CONCLUSIONS: The two devices have similar hemostasis outcomes for LBVA following LAAO, but each has unique considerations. LockeT was associated with fewer access-site complications and device failures; Perclose was associated with faster TTA. Nevertheless, additional studies are still needed.
The authors' abstract, as published at the source. Journal of Interventional Cardiac Electrophysiology, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Emergency Medical Services
Emergency Medical ServicesHealth Professions